You are here

Alkermes

Alkermes begins Phase II trial of ALKS 2680 for narcolepsy type 1

Clinical Trials Arena

Thu, 04/25/24 - 11:26 am

clinical trials

Alkermes reports data from Phase Ib narcolepsy treatment trial

Clinical Trials Arena

Wed, 04/10/24 - 06:00 pm

clinical trials

Alkermes and Jazz: Two Different Approaches to Neuroscience, Oncology Portfolios

BioSpace

Tue, 03/12/24 - 11:02 am

With good news on Lybalvi, Alkermes sees 10% share price increase

Fierce Pharma

Fri, 02/16/24 - 11:21 am

biopolar disorder

JPM24: After 'clearing the decks,' Alkermes ready to roll as pure-play neuroscience company

Fierce Pharma

Wed, 01/10/24 - 09:44 am

Alkermes Spins Off Oncology Business with $275M to Focus on Neuroscience

BioSpace

Wed, 11/15/23 - 11:58 am

Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680

Drugs.com

Tue, 10/10/23 - 11:47 pm

Alkermes fends off generic versions of Vivitrol until 2027

Clinical Trials Arena

Thu, 08/31/23 - 06:07 pm

Teva Pharmaceutical

Alkermes, nearing oncology split, posts big Q2 sales gain after winning J&J arbitration case

Fierce Pharma

Wed, 07/26/23 - 06:37 pm

Sarissa Capital urges Alkermes shareholders to vote for its board nominees after years of rejections

Fierce Pharma

Mon, 06/12/23 - 10:21 am

Sarissa Capital

Alkermes, after arbitration win over J&J, jacks up revenue forecast by $425M

Fierce Pharma

Wed, 06/7/23 - 10:18 am

Alkermes to hive off oncology business

Pharma Letter

Thu, 11/3/22 - 10:55 am

With millions on the line, Alkermes, J&J start arbitration over drug delivery tech dispute

Fierce Pharma

Fri, 04/22/22 - 10:32 am

J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'

Endpoints

Tue, 11/9/21 - 11:35 pm

Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs

Motley Fool

Sun, 06/13/21 - 10:44 pm

Alpine Immune Sciences

ASCO 2021 – Alkermes’s disappointment hones melanoma niche focus

EP Vantage

Fri, 06/4/21 - 10:41 am

nemvaleukin alfa

After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi

Pharmaforum

Thu, 06/3/21 - 10:37 am

Alkermes prepares for uncertain launch as FDA finally clears schizophrenia drug

Biopharma Dive

Tue, 06/1/21 - 10:37 pm

bipolar disorder

As Alkermes shines light on early cancer, neuro assets, biotech searches for collabs, strategic ops

Fierce Biotech

Fri, 03/26/21 - 10:47 am

immuno-oncology

Why Alkermes' Q4 Results Were Better Than They Might Seem

Motley Fool

Thu, 02/11/21 - 10:25 pm

Pages